Us Bancorp \De\ Ngm Biopharmaceuticals Inc Transaction History

Us Bancorp \De\

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.6 - $1.31 $7,650 - $16,703	12,751 New	12,751 $10,000
Q2 2023 Aug 09, 2023	SELL	$2.44 - $4.53 $2,949 - $5,476	-1,209 Reduced 72.79%	452 $1,000
Q1 2023 May 09, 2023	BUY	$3.72 - $5.4 $1,755 - $2,548	472 Added 39.7%	1,661 $6,000
Q4 2022 Feb 13, 2023	BUY	$3.41 - $12.93 $3,583 - $13,589	1,051 Added 761.59%	1,189 $5,000
Q3 2022 Oct 27, 2022	BUY	$12.59 - $17.67 $919 - $1,289	73 Added 112.31%	138 $2,000
Q2 2022 Aug 01, 2022	SELL	$10.58 - $17.5 $4,454 - $7,367	-421 Reduced 86.63%	65 $1,000
Q1 2022 May 11, 2022	BUY	$13.81 - $18.6 $2,444 - $3,292	177 Added 57.28%	486 $7,000
Q4 2021 Feb 11, 2022	BUY	$17.26 - $22.02 $3,503 - $4,470	203 Added 191.51%	309 $5,000
Q3 2021 Nov 10, 2021	BUY	$20.15 - $26.19 $2,135 - $2,776	106 New	106 $2,000
Q2 2021 Aug 05, 2021	SELL	$15.06 - $30.03 $4,066 - $8,108	-270 Closed	0 $0
Q4 2020 Feb 04, 2021	BUY	$16.21 - $31.44 $4,376 - $8,488	270 New	270 $8,000
Q3 2020 Nov 10, 2020	SELL	$15.59 - $19.97 $701 - $898	-45 Closed	0 $0
Q2 2020 Aug 07, 2020	BUY	$11.97 - $23.47 $538 - $1,056	45 New	45 $1,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.